Infliximab clinical trials
Also written Remicade, SCH 215596 and TA-650.
Includes 2 studies of BCD-055 and 2 studies of GP1111.
How each study uses Infliximab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Infliximab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 24 Aug 1998 · REMICADE · BLA 103772 (FDA, Drugs@FDA)
- European Union
- 13 Aug 1999 · Remicade · EMEA/H/C/000240 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
241 studies that test it; most in 2003 (18)
| Year | Studies |
|---|---|
| 1995 | 1 |
| 1996 | 2 |
| 1997 | 1 |
| 2000 | 1 |
| 2001 | 4 |
| 2002 | 8 |
| 2003 | 18 |
| 2004 | 5 |
| 2005 | 14 |
| 2006 | 14 |
| 2007 | 18 |
| 2008 | 11 |
| 2009 | 9 |
| 2010 | 10 |
| 2011 | 5 |
| 2012 | 14 |
| 2013 | 12 |
| 2014 | 6 |
| 2015 | 10 |
| 2016 | 11 |
| 2017 | 7 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 10 |
| 2021 | 9 |
| 2022 | 8 |
| 2023 | 7 |
| 2024 | 4 |
| 2025 | 7 |
| 2026 | 7 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 86 · Other 163
Merck Sharp & Dohme LLC (25) · Centocor, Inc. (20) · Tanabe Pharma Corporation (7) · Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives (5) · Emory University (5) · Celltrion (5) · Massachusetts General Hospital (4) · National Institute of Allergy and Infectious Diseases (NIAID) (4)
Often tested with
Tested in the same studies.
Adalimumab (18) · Etanercept (13) · Methotrexate (12) · Azathioprine (9) · Golimumab (8) · Certolizumab Pegol (7) · Tocilizumab (6) · Abatacept (5)
Related medicines
As reviewed, each with the page that says it.
- One of Antibodies, Monoclonal source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 8
Studies that test Infliximab.
- Nov 2026Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease PatientsPhase 4 · Taizhou Mabtech Pharmaceutical Co.,Ltd
- Dec 2026Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)Phase 2 · University of Liverpool
- Dec 2026Efficacy and Safety of Formulation Switching Between SC Infliximab and IV Infliximab in Patients With CDNot applicable · Asan Medical Center
- Mar 2027PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel DiseaseNot applicable · Pontificia Universidad Catolica de Chile
- Mar 2027Topical Infliximab in Eyes With Penetrating KeratoplastyPhase 1/2 · Centre hospitalier de l'Université de Montréal (CHUM)
- May 2027Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO TrialPhase 2 · Asian Institute of Gastroenterology, India
- Jun 2027PD-1 Antibody Therapy + Infliximab for Metastatic MelanomaPhase 2 · Massachusetts General Hospital
- Jul 2027Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing PolychondritisPhase 2 · University of Pennsylvania
Studies
Open first, then newest update. How each study uses Infliximab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 249
- PROactive and Early Infliximab Monitoring and oPTimization in Inflammatory Bowel DiseaseRecruitingNot applicablePontificia Universidad Catolica de ChileNCT06758024Written as InfliximabHow we know
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingPhase 4IsalaNCT06031233Written as InfliximabHow we know
- Cognitive Dysfunction and Inflammation in Depression: Experimental Inhibition Via InfliximabRecruitingPhase 2Massachusetts General HospitalNCT06136546Written as InfliximabHow we know
- Infliximab for Immune Checkpoint Inhibitor Associated AKIRecruitingPhase 4Massachusetts General HospitalNCT07683975Written as InfliximabHow we know
- Infliximab for Cytokine Release Syndrome Prophylaxis During Teclistamab or Talquetamab Therapy in Patients With Relapsed or Refractory MyelomaRecruitingPhase 2Naresh BummaNCT07657312Written as InfliximabHow we know
- Post-marketing Registry Study of Infliximab for Injection in Chinese Pediatric Crohn's Disease PatientsRecruitingPhase 4Taizhou Mabtech Pharmaceutical Co.,LtdNCT05906576Written as InfliximabHow we know
- Pragmatic, Open-Label Study to Pilot Evaluation for Clinical Trials in Relapsing PolychondritisRecruitingPhase 2University of PennsylvaniaNCT06941376Written as InfliximabHow we know
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With CancerRecruitingPhase 1M.D. Anderson Cancer CenterNCT03819296Written as InfliximabHow we know
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder ArthroplastyRecruitingPhase 2NYU Langone HealthNCT07138898Written as InfliximabHow we know
- Randomised Treatment of Acute Pancreatitis With Infliximab: Double-blind, Placebo-controlled, Multi-centre Trial (RAPID-I)RecruitingPhase 2University of LiverpoolNCT03684278Written as Infusion of 5 mg/kg InfliximabHow we know
- Safety and Efficacy of Topical Infliximab in Autoimmune Dry Eye DiseaseNot yet recruitingPhase 2Instituto de Oftalmología Fundación Conde de ValencianaNCT07671222Written as Infliximab 0.1%How we know
- Medical Treatment Versus Surgery in Stricturing Small Bowel Crohn's DiseaseNot yet recruitingNot applicableNantes University HospitalNCT05584228Written as Azathioprine + infliximabHow we know
- Treatment of Rheumatoid Arthritis With DMARDs: Predictors of ResponseRecruitingPhase 3University of NebraskaNCT03414502Written as InfliximabHow we know
- Infliximab Therapy for Dolichoectactic Vertebrobasilar AneurysmsRecruitingPhase 1/2University of California, San FranciscoNCT02638701Written as InfliximabHow we know
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as InfliximabHow we know
- Anti-Inflammatory Challenge in SchizophreniaRecruitingPhase 4Emory UniversityNCT05823532Written as InfliximabHow we know
- Topical Infliximab in Eyes With Penetrating KeratoplastyRecruitingPhase 1/2Centre hospitalier de l'Université de Montréal (CHUM)NCT05180994Written as Topical infliximabHow we know
- Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained RemissionRecruitingNot applicableMarmara UniversityNCT07491913Written as InfliximabHow we know
- Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's DiseaseNot yet recruitingPhase 4Chinese Medical AssociationNCT07417696Written as Palmitoleic Acid + InfliximabHow we know
- Combination Therapy With Infliximab and Tofacitinib for Acute Severe Ulcerative Colitis - CINTO TrialNot yet recruitingPhase 2Asian Institute of Gastroenterology, IndiaNCT07297069Written as InfliximabHow we know
See all 249 studies that test Infliximab →
Given beside what is tested · 7 — Infliximab is usual care or a partner of the new treatment
- TNFi Plus Low-Dose Upadacitinib vs TNFi Intensification in Crohn's Disease With Suboptimal ResponseRecruitingPhase 4Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT07510191Written as Standard-Dose infliximabHow we know
- Precise Infliximab Exposure and Pharmacodynamic ControlRecruitingPhase 2/3Children's Hospital Medical Center, CincinnatiNCT05660746Written as InfliximabHow we know
- Efficacy of Mesalazine Combined With Biologics in the Treatment of Moderate to Severe Ulcerative ColitisCompletedPhase 4Sixth Affiliated Hospital, Sun Yat-sen UniversityNCT05205603Written as InfliximabHow we know
- Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney TransplantationCompletedNot applicableInstitute for Clinical and Experimental MedicineNCT02711202Written as RemicadeHow we know
- Efficacy and Mechanism of FMT in the Treatment of Inflammatory Bowel Disease: an Open-label Randomized Controlled StudyActive, not recruitingNot applicableShanghai 10th People's HospitalNCT07149441Written as infliximabHow we know
- N-3 Polyunsaturated Fatty Acids Prevent Postoperative Recurrence of Crohn's DiseaseStatus unknownNot applicableSixth Affiliated Hospital, Sun Yat-sen UniversityNCT04761952Written as infliximabHow we know
- Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies in Chronic Inflammatory DiseasesTerminatedNot applicableUniversity Hospital, LilleNCT03370601Written as InfliximabHow we know
As the comparator · 22 — what is tested is compared with Infliximab
- PHOENIX-ECP- Extracorporeal Photopheresis for Immune-related Colitis and/or Hepatitis in Advanced Melanoma With Inadequate Response to Steroid ExposureNot yet recruitingPhase 2Therakos LLCNCT07619898Written as InfliximabHow we know
- Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis(UPRISE)RecruitingPhase 4Xijing Hospital of Digestive DiseasesNCT07550673Written as InfliximabHow we know
- Combined Immunosuppression for Pediatric Crohn's DiseaseRecruitingPhase 4Children's Hospital of Fudan UniversityNCT05043870Written as InfliximabHow we know
- The Efficacy and Safety of Infliximab Combination With Azathioprine in Crohn's Disease in ChildrenNot yet recruitingNot applicableThe Children's Hospital of Zhejiang University School of MedicineNCT07424040Written as Infliximab monotherapyHow we know
- Akkermansia Muciniphila Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's DiseaseNot yet recruitingPhase 4Chinese Medical AssociationNCT07415473Written as InfliximabHow we know
- AppenDectomy Vs ANti TNF-a in Inducing Clinical and EnDoscopic Remission in Left-sided Ulcerative ColitisNot yet recruitingNot applicableFederico II UniversityNCT05931458Written as InfliximabHow we know
- Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or MelanomaActive, not recruitingPhase 1/2M.D. Anderson Cancer CenterNCT04407247Written as InfliximabHow we know
- EPIC- Extracorporeal Photopheresis (ECP) for Immune-related ColitisWithdrawnPhase 2Therakos LLCNCT06646016Written as InfliximabHow we know
- A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)CompletedPhase 3Incyte CorporationNCT03112603Written as InfliximabHow we know
- Biologic Tapering Study of TNF Inhibitors in Axial SpondyloarthritisActive, not recruitingPhase 4University Health Network, TorontoNCT05115903Written as Standard dose of TNFiHow we know
- Immune Modulators for Treating COVID-19CompletedPhase 3Daniel BenjaminNCT04593940Written as InfliximabHow we know
- Rheumatoid Arthritis Treatment After First Anti-TNF INvestiGationTerminatedPhase 4Mario Negri Institute for Pharmacological ResearchNCT03100253Written as InfliximabHow we know
- Exclusive Enteral Nutrition vs. Infliximab in Chinese CD PatientsWithdrawnPhase 4Children's Hospital of Fudan UniversityNCT04530877Written as InfliximabHow we know
- A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) InhibitorsCompletedPhase 3Hoffmann-La RocheNCT02136069Written as InfliximabHow we know
- To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid ArthritisCompletedPhase 3CelltrionNCT03707535Written as RemicadeHow we know
- A Study to Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or AdalimumabTerminatedPhase 2Genentech, Inc.NCT00808210Written as InfliximabHow we know
- Thalidomide Versus Infliximab in New Onset Crohn's Disease With Poor Prognostic FactorsTerminatedPhase 3IRCCS Burlo GarofoloNCT03221166Written as InfliximabHow we know
- A Study Comparing SB2 to Remicade® in Subjects With Moderate to Severe Rheumatoid Arthritis Despite Methotrexate TherapyCompletedPhase 3Samsung Bioepis Co., Ltd.NCT01936181Written as Remicade (infliximab)How we know
- Two Therapeutic Strategies for the Maintenance of Remission in Patients With Ulcerative ColitisStatus unknownPhase 4Istituto Clinico HumanitasNCT03151525Written as InfliximabHow we know
- A Phase II Efficacy Study in Fistulizing Crohn's Disease PatientsCompletedPhase 2Novartis PharmaceuticalsNCT01355614Written as InfliximabHow we know
Showing 20 of 22.
Codes
What other systems call Infliximab · ClinicalTrials.gg INT006568
- MeSH (NLM) D000069285InfliximabConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) B72HH48FLUINFLIXIMABConfirmed FDA, NLM, Wikidata
- RxNorm 191831Confirmed FDA, Wikidata
- Wikidata Q415264infliximabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1789InfliximabOne source FDA
- DrugBank DB00065One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000069285 | Infliximab | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | B72HH48FLU | INFLIXIMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 191831 | — | Confirmed FDA, Wikidata |
| Wikidata | Q415264 | infliximab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1789 | Infliximab | One source FDA |
| DrugBank | DB00065 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.